7RXPC_chart.pngRadient Pharmaceuticals Corporation (PINK:RXPC) is the developer and marketer of a non-invasive cancer blood test kit. The company is not in a good place right now, but the last several sessions may bring some hope to shareholders.

Yesterday, RXPC closed up 23.08% at $0.0048 after approximately 25.6 million shares had been traded.[BANNER]

The company’s stock used to trade a lot higher just a few months ago. Around May, the price was moving near the $0.40 mark.

RXPC has had some legal problems which led to a settlement. The unfavorable terms of the said settlement played a role in the severe price drop which left RXPC in the sub-penny zone.

The recent bounce seems to be due to the announcement of a regional distributor partner agreement between RXPC and Ts Pharm, Inc.

0RXPC_logo.pngWhile there is no doubt the agreement is a positive development, the shadow of the settlement may dampen the spirits. Today, RXPC opened higher than yesterday’s close, but at the time of this writing RXPC is down 16.67%.